2011 as 2010 was a very tricky year for in vitro diagnostic companies: crisis is everywhere. However, DIAGAST plays its game well in 2011 by posting an increase of 15% Read more
On January 31st, DIAGAST has received the FDA approval for the use of 3 additional bioreactors (65, 250 and 380 liters) in the manufacture process of monoclonal antibodies. Read more
DIAGAST the Blood Matching Company had the pleasure to welcome you to the 22nd Regional Congress of the ISBT, Asia (International Society of Blood Transfusion) that held on november 19-23, in Taipei, Taiwan. Read more
FRESENIUS KABI , our exclusive distributor for the Brazilian market, attended HEMO 2011 , the 33nd Congress of the Brazilian Society of Hematology, held November 10-13 in Sao Paulo. The high level of quality of this event confirmed it as the most importan Read more
DIAGAST your privileged partner in Immunohaematology had the pleasure to welcome you on its booth during the congress of the I.S.B.T.I. (Indian Society of Blood Transfusion and Immunohaematology) that held in Panchkula (India) from October 31st to novembe Read more
QWALYS Connect is the latest technologic novelty entirely created by DIAGAST engineers team: greater efficiency, greater user-friendliness and greater performance. Read more
The official launching of QWALYS XL took place during the last regional congress of the I.S.B.T. (International Society of Blood Transfusion), which was held June 18-22 in Lisbon. This brand new automated system offers a significant improvement in ... Read more
The registration certificate for medical device (according to Directive 98/79/EC) certifies that our Anti-D(RH1) IgM I has been inspected by the S.F.D.A.’office and is permitted to register on the Read more
